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Abstract
Background: Alpha synuclein (SNCA) has been linked to neurodegenerative diseases (synucleinopathies) that
include Parkinson’s disease (PD). Although the primary neurodegeneration in PD involves nigrostriatal
dopaminergic neurons, more extensive yet regionally selective neurodegeneration is observed in other
synucleinopathies. Furthermore, SNCA is ubiquitously expressed in neurons and numerous neuronal systems are
dysfunctional in PD. Therefore it is of interest to understand how overexpression of SNCA affects neuronal function
in regions not directly targeted for neurodegeneration in PD.
Results: The present study investigated the consequences of SNCA overexpression on cellular processes and
functions in the striatum of mice overexpressing wild-type, human SNCA under the Thy1 promoter (Thy1-aSyn
mice) by transcriptome analysis. The analysis revealed alterations in multiple biological processes in the striatum of
Thy1-aSyn mice, including synaptic plasticity, signaling, transcription, apoptosis, and neurogenesis.
Conclusion: The results support a key role for SNCA in synaptic function and revealed an apoptotic signature in Thy1-
aSyn mice, which together with specific alterations of neuroprotective genes suggest the activation of adaptive
compensatory mechanisms that may protect striatal neurons in conditions of neuronal overexpression of SNCA.
Keywords: α-synuclein, apoptosis, neuroprotection, Parkinson’s disease, Alzheimer’s disease, synaptic plasticity, vesi-
cle release, diabetes
Background
Abnormal accumulation of the pre-synaptic protein a-
synuclein (SNCA) is a hallmark of several neurodegen-
erative disorders including the second most frequent
neurodegenerative disease Parkinson’s disease (PD) [1].
Neurodegeneration in PD is predominant in the sub-
stantia nigra pars compacta (SNc), but cell loss and
Lewy Body (LB) formation also occur in other brain and
peripheral tissues [2]. Familial forms of PD have been
linked to mutations in SNCA, and also to multiplications
of the locus encompassing the SNCA gene, which lead
to increased levels of SNCA expression indicating that
the wild-type (wt) protein can be pathogenic if produced
in excess [3]. Furthermore, Genome Wide Association
Studies (GWAS) have consistently identified the SNCA
gene as most associated with PD risk [4]. In most synu-
cleinopathies, SNCA aggregates form in neurons [5].
Transgenic (tg) murine models expressing human SNCA
under neuronal promoters reproduce some phenotypic
features of PD such as inclusion formation, motor and
* Correspondence: yofrecabeza@gmail.com
1Department of Pathology and Environmental Health Sciences, The Geffen
School of Medicine and School of Public Health, University of California, Los
Angeles, 650 Charles E. Young Dr. S, CHS 71-295; Los Angeles, CA 90095,
USA
Full list of author information is available at the end of the article
Cabeza-Arvelaiz et al. Molecular Neurodegeneration 2011, 6:83
http://www.molecularneurodegeneration.com/content/6/1/83
© 2011 Cabeza-Arvelaiz et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.non-motor impairments, loss of striatal dopamine (DA),
and, in a few tg lines, nigrostriatal degeneration (For
review see: [6,7]). Mice expressing human wild-type
SNCA under the Thy1 promoter (Thy1-aSyn mice)
express high level of mRNA and protein in neurons
throughout the brain [8] and develop proteinase K-resis-
tant SNCA aggregates [9,10]. These mice show a 40%
loss of DA in the striatum by 14 months of age [11].
We have shown that these mice display early and pro-
gressive sensorimotor anomalies, abnormal response to
stimulants, olfactory deficits and digestive dysfunction
before the loss of striatal DA [6,7,10,12-14]. In addition,
they show profound anomalies of cortico-striatal trans-
mission [15,16], suggesting alterations within motor cor-
tico-subcortical loops. Whole transcriptome analysis
provides a valuable alternative approach for the detec-
tion of key changes that might not be practical to
attempt by directed single-gene/protein approaches. Pre-
vious studies have evaluated alterations in gene expres-
sion patterns in cells from SNc and striatal tissues from
transgenic mice overexpressing SNCA in the SNc under
different promoters [17,18]. However, little is known of
the effects of SNCA overexpression in the striatum
itself, the region that contains the axon terminals of
dopaminergic (DArgic) neurons and mediates the beha-
vioral effects of DA depletion in PD.
To gain a better understanding of the consequences of
excessive SNCA expression on basal ganglia function,
we performed transcriptome analysis of striatal tissue
from male Thy1-aSyn-mice and wt littermates. The data
further support a key role for SNCA in synaptic func-
tion and also reveal alterations in multiple biological
processes including signaling, apoptosis, and neurogen-
esis, which may be related to both functional deficits
resulting from SNCA overexpression and the sparing of
striatal neurons in most synucleinopathies.
Results and discussion
Differentially regulated genes and functional categories
To understand how increased SNCA expression causes
neuronal cellular dysfunction, we analyzed gene
expression in the striatum, the major target of the
nigrostriatal DArgic projections and a brain region that
plays a key role in the control of motor, affective and
cognitive functions but does not degenerate in PD [19].
We elected to examine changes in gene expression in
the striatum of 6-month-old mice because, as shown in
our previous publications [9-12,14], the Thy1-aSyn mice
begin the show progressive behavioral impairments from
2 months of age but do not show significant DArgic
loss in the striatum until 14 months of age [11]. There-
fore, the time point chosen for these studies corre-
sponds to a pre-manifest phase of PD, when neuronal
dysfunction due to SNCA pathology is present, but DA
is not yet lost.
In order to have sufficient mRNA to generate tran-
script concentrations in the range required to be
detected safely above background levels, total RNA from
groups of 6 tg Thy1-aSyn or 6 wt mice were pooled.
Pooling has the added advantage that it minimizes indi-
vidual variations as a source of gene-expression variance,
which impacts the identification of differentially
expressed genes by DNA microarrays [20]. Genes differ-
entially regulated in Thy1-aSyn mice compared to wt lit-
termates were identified by whole transcriptome
analysis. The relative fold increased expression of
human SNCA in the Thy1-aSyn mice used, as assessed
by qRT-PCR, is shown in Table 1. The SNCA primer
set used hybridized to human SNCA and mouse Snca
mRNAs, albeit less efficiently to the latter, therefore
showing relative differences in total SNCA mRNA
expression between wt and tg mice. However, the very
high level of expression of SNCA mRNA only results in
a 50% increased level of total SNCA protein in this
region in the Thy1-aSyn mice based on quantitative
immunohistochemical analysis (Franich, Richter, and
Chesselet unpublished observations). This suggests that
the model is suitable to evaluate the effects of excess
SNCA in the range observed in humans with SNCA
gene duplication leading to familial forms of PD [3].
Notably, our mouse microarray data rule out a loss of
transcriptional expression of endogenous Snca in Thy1-
Table 1 Array data quality control and differentially-regulated genes in ASO mice
Mice Genotype SNCA expression Data quality control Altered genes
species fold change (mean ± sd) source % calls (present) intensity (mean ± sd) up down total
ASO mSnca
a 0.9 ± 0.1 All
c 57.5 197 ± 445 349 484 833
hSNCA
b 155 ± 85 D.E.G.
d 84.1 220 ± 271 96 137 233
wt hSNCA 1.1 ± 0.5 All
c 58.6 194 ± 425 0 0 0
mSnca 1.0 ± 0.0 D.E.G.
d 91.3 223 ± 295 0 0 0
Abbreviations: ASO: a-Synuclein (SNCA) overexpressing; wt; wild type; D.E.G.: differentially expressed gene
Notes: a- mSnca detected by 3 probe sets in theMoe-430A chip; b- hSNCA measured by qRT-PCR in 3 wt and 3 ASO mice (Figure 2B); c- Include all changed
genes P < 0.005; d- Selection criteria for D.E.G. (1) gene is present in at least one of the mice groups examined and (2) Fold change > 1.52 (Signal log2 ratio >
0.6), p < 0.005.
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microarray was assessed (see Table 1 and Additional file
1 Figure S1) by inspecting: (1) the percentage of genes
called present (include all changed genes p < 0.005),
which was comparable and above 50% for both mice
groups (wt and tg), and (2) the mean signal intensity,
which was quite similar for both mice groups. After
pairwise comparison, a list of 833 genes altered in
Thy1-aSyn mice was generated. Further filtering to
remove genes with fold change below 1.5, or that were
called absent in both groups reduced the list to 263
genes, which was reduced further to the final 233 differ-
entially expressed genes after removal of redundant
genes. The number of upregulated genes was 96 genes
whereas 137 genes were downregulated (Table 1), indi-
cating that SNCA overexpression effects are mediated
more prominently through negative regulation of tran-
scription. The complete list of differentially expressed
genes with respective test data is available (see Addi-
tional file 2 Table S1). To identify functional categories
overrepresented in the lists of genes altered in Thy1-
aSyn mice we used DAVID [21], which implements the
Gene Ontology (GO) terms in three structured ontolo-
gies that relate gene products on the basis of their asso-
ciated biological processes (BPs), cellular components
(CC), and molecular functions (MFs); it also incorpo-
rates the Genetic Association Database (GAD) of
human diseases, which allows for the identification of
genes associated with human diseases [22]. The signifi-
cant overrepresentation in GO and GAD of the 224
genes that had meaningful annotations pointed to
alterations in gene expression between Thy1-aSyn and
wt mice. These 224 genes were categorized into BPs,
CCs and MFs and multiple overlapping GO terms
(referred to as functional categories hereafter) and dis-
eases were identified; 28 representative and significantly
represented groups (p < 0.05) were selected and are
listed in Table 2; these groups were then organized into
six ad hoc function-related groups, with considerable
overlap between them, and are shown in Table 2. Each
of these groups will be discussed separately below.
Validation of Microarray results by alternative methods
Microarray data was validated by qRT-PCR analysis of a
total of 25 selected genes. 18 selected genes were vali-
dated using pooled total RNAs from Thy1-aSyn and wt
mice (Figure 1A). Similarly, 11 of these 18 genes plus 7
other different genes were also validated using total
RNA from a separate cohort of individual mice (n = 3)
to assess biological variability in gene expression (Figure
1B). In addition, the microarray and qRT-PCR results
for the highly expressed transthyretin (Ttr) gene were
validated using ELISA [23] to measure Ttr protein levels
in the same cohort of individual mice (Figure 2A) and
compared to the levels of SNCA gene expression (Figure
2B). Genes were selected for PCR validation mainly for
the following reasons: they encompass low, moderate
and high intensity signal genes and they form part of
one or more of the functional categories (listed in Table
2) that were significantly over-represented in the list of
differentially-expressed genes. Although not exhaustive,
we consider this list of genes representative of the total
gene expression profile in affected pathways. In particu-
lar, it encompasses at least 3 genes from those overlap-
ping pathways that have been associated with
neurodegeneration and the PD phenotype, summarized
in Figure 3. The qRT-PCR-analyzed genes are distribu-
ted among the functional categories as follows: A- Vesi-
cles and Synapse (Srebf2, Bdnf, Stx1A, Adora2A), B-
Synaptic function (Bdnf, Stx1A, Ywhag, Drd2, Adora2A,
Pde7b), C- Apoptosis (Bdnf, Nr4a2, Mef2c, Adora2A,
Dhcr24, Ttr), D- Behavior (Nr4a2, Rasd2, Drd2,
Adora2A, Ttr, Trh, Bdnf, Cckbr), and E- Vasculature
and lipid metabolism (Mef2c, Srebf2, Dhcr24); and a few
other categories, which for reasons of space we chose
not to show in Figure 3: Neurogenesis (Bdnf, Nr4a2,
Phgdh), Cell cycle (Pttg1, Ptprk, Dhcr24, Ywhag), Signal-
ing (Ptprk, Pde7b, Drd2, Adora2A, Trh, Ywhag), Cell
growth/proliferation (B d n f ,M e g 3 ,N o v ,P t p r k ), Tran-
scription (Med1, Mef2c, Nr4a2, Srebf2), Response to oxi-
dative stress (Gpx3, Dhcr24, Nr4a2). In addition, we
checked 4 “orphan” genes, not associated with any sig-
nificant category, but which could still be relevant to PD
pathogenesis including, Ckmt1 (Creatine metabolism
and energy generation), Tnnt1 (Muscle contraction),
Psb6 and Psmc4 (Proteasome and cell cycle check
point). Validation in individual mice was done on blocks
of striatal tissue carefully dissected out from tissue slices
to eliminate potential contamination from adjacent tis-
sue, including the subventricular zone and choroid
plexus. The expression of 3 of these genes in Thy1-
aSyn; namely, Psmc4 (Proteasome (prosome, macropain)
26S subunit, ATPase, 4) in pooled samples (Figure 1A)
plus Adora2a (Adenosine A2a receptor) and Med1
(mediator complex subunit) in non-pooled samples (Fig-
ure 1B) did not differ significantly from wt mice by
qRT-PCR and therefore disagree with the microarray
results. In addition, Meg3 (Maternally expressed 3,
imprinted maternally expressed untranslated mRNA)
and Mef2c (myocyte enhancer factor 2c) changed in
opposite directions by the two methods. Nevertheless,
the expression of most genes in the Thy1-aSyn mice
group with both pooled and non-pooled RNA was gen-
erally similar between the microarray and qRT-PCR
analyses, as indicated by the assessment of correlation
using the Pearson’s test which found strong and signifi-
cant correlation between microarray and qRT-PCR mea-
sured expression values in A (r
2 = 0.7288, p < 0.0001)
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2 = 0.7354, p < 0.0001). These data suggest that
the direction and magnitude of change of gene expres-
sion levels (i.e. either up or down regulation) is accu-
rately predicted by comparison of microarray expression
values.
Because the main purpose of this study is to assess
changes in transcriptome, individual changes were not
systematically validated at the protein level. However,
we did measure the protein levels of transthyretin
because upregulation of this gene has been associated
w i t hn e u r o p r o t e c t i o ni nA l z heimer disease [24], and its
high induction in the striatum of Thy1-aSyn mice was
unexpected and of potential functional significance. The
results, shown in Figure 2A, indicate that Ttr protein
levels are significantly elevated in individual Thy1-aSyn
mice and appear to be associated with the levels of
SNCA mRNA as indicated by the assessment of correla-
tion using the Pearson’s test which found significant
correlation (r
2 = 0.6791, p < 0.043) between the levels of
Ttr protein (Figure 2A) and SNCA mRNA levels (Figure
2B).
SNCA overexpression affects signaling pathways
associated with the pathophysiology of
neurodegenerative diseases
The first group of functional categories influenced by
SNCA overexpression in Table 2 encompasses major
signal transduction pathways such as the mitogen-acti-
vated protein kinases (MAPK) and Ca2+ signaling cas-
cades that regulate multiple cellular processes [25-27].
Protein phosphorylation is a preponderant regulatory
mechanism of signal transduction cascades in eukaryotic
cells that is catalyzed by kinases and reversed by protein
phosphatases [26]. Not surpr i s i n g l y ,h a l fo ft h eg e n e s
affected in Thy1-aSyn mice are phosphoproteins includ-
ing kinases, phosphatases and phosphodiesterases
Table 2 Enriched functional categories for genes differentially regulated by a-synuclein
Database identifier Functional category (Enriched GO and GAD terms) Number of changed genes
up down pvalue
MF SP_PIR_KEY phosphoprotein 49 64 8E-07
BP GO:0007242 intracellular signaling cascade 11 8 5E-02
BP KEGG_PATH mmu04010:MAPK signaling pathway 5 4 3E-02
BP KEGG_PATH mmu04020:Calcium signaling pathway 3 5 1E-02
CC GO:0045202 synapse 7 10 3E-06
CC GO:0005856 cytoskeleton 12 10 4E-02
CC GO:0031410 cytoplasmic vesicle/vesicle-mediated transport
a 8 7 1E-02
BP GO:0048167 regulation of synaptic plasticity 3 3 4E-04
BP GO:0007267 cell-cell signaling 4 5 3E-02
BP GO:0006897 endocytosis 4 3 5E-02
BP GO:0045941 positive regulation of transcription 5 10 3E-03
BP GO:0042127 regulation of cell proliferation 8 9 2E-03
MF GO:0005520 IGF binding/growth factor binding
b 1 4 7E-03
BP GO:0051259 protein oligomerization 2 3 1E-02
BP GO:0042981 regulation of apoptosis 6 11 2E-03
BP GO:0007610 behavior 10 13 7E-04
BP GO:0007626 locomotory behavior 5 8 4E-03
BP GO:0008344 adult locomotory behavior 1 4 8E-03
BP GO:0007631 feeding behavior 5 7 5E-04
BP GO:0001975 response to amphetamine 2 1 2E-02
BP GO:0030146 diuresis/excretion
c 3 1 2E-03
MF GO:0005179 hormone activity 1 5 2E-02
BP GO:0016125 sterol metabolic process/cholesterol metabolism
d 5 4 2E-02
BP GO:0030182 neuron differentiation 10 10 9E-07
BP GO:0031175 neuron projection development 7 6 2E-05
BP GO:0001944 vasculature development 2 6 4E-02
D G_A_DB_D neurological diseases 4 5 5E-02
D G_A_DB_D diabetes, types 1 and 2 3 6 5E-02
Abbreviations: D: disease; G_A_DB_D:Genetic_Association_DataBase_D; GO: Gene Ontology; BP: Biological process; MF: Molecular function; CC: Cell. component;
KEGG_PATH: KEGG_PATHWAY; SP_PIR_KEY: SP_PIR_KEYWORDS;
Notes: a- GO:0016192; b- GO:0019838; c- GO:0007588; d- SP_PIR_KEYWORDS: cholesterol metabolism.
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Page 4 of 16Figure 1 Corroboration of microarray results for differentially
expressed genes. Confirmation of the changes of selected
microarray differentially expressed genes by comparison to the
changes assessed by quantitative real-time polymerase chain
reaction (qRT-PCR) using: A- pooled RNA from wild-type (wt) and a-
synuclein (SNCA) overexpressing transgenic (tg) mice groups; B- RNA
from individual wt and tg mice. The qRT-PCR average fold changes
of selected genes in tg mice striata normalized to Gapdh
(Glyceraldehyde-3-phosphate dehydrogenase), and relative to
expression in wt mice (dotted line) are shown (mean ± SEM); ns
(not significantly different expression between tg and wt mice,
using a t-test, n = 3, p > 0.05); SEM values in (A) show qRT-PCR
technical variation in, and in (B) show variation between mice plus
qRT-PCR technical variation). Pearson’s test found significant
correlation between microarray and qRT-PCR results in A (r
2 =
0.7288, p < 0.0001) and B (r
2 = 0.7354, p < 0.0001). Ttr
(transthyretin), Phgdh (3-phosphoglycerate dehydrogenase), Pde7b
(phosphodiesterases 7b), Tnn1 (troponin t1), Adora2a (adenosine
A2a receptor), Meg3 (Maternally expressed 3), Drd2 (dopamine
receptor 2), Rasd2 (rasD family, member 2), Psmb6 (proteasome
(macropain) subunit, b 6), Med1 (mediator complex subunit), Ptprk
(protein tyrosine phosphatase, receptor, K), Pttg1 (pituitary tumor-
transforming 1), Nov (Nephroblastoma Overexpressed), Pparbp
(peroxisome proliferator activated receptor binding protein), Stx1a
(syntaxin 1a), Nr4a2, Psmc4 (proteasome (macropain) 26S subunit,
ATPase, 4), Mef2c (myocyte enhancer factor 2c), Cckbr
(cholecystokinin B receptor), Dhcr24 (24-dehydrocholesterol
reductase), Ckmt1 (creatine kinase, mitochondrial 1), Srebf2 (sterol
regulatory element-binding factor 2), Trh (thyrotropin-releasing
hormone), Bdnf (brain derived growth factor), Gpx3 (glutathione
peroxidase 3), Ywhag (Y-3-monooxygenase/W 5-monooxygenase
activation protein, g polypeptide).
Figure 2 Validation of microarray and qRT-PCR results for the
highly expressed transthyretin (Ttr) gene. The confirmation of
the differential expression of Ttr was achieved by measuring
striatum Ttr protein levels by ELISA in individual wt (wild-type) mice
and aso (a-synuclein (SNCA) overexpressing or Thy1-aSyn mice). A-
The average Ttr protein levels in the striata from Thy1-aSyn mice
and wt mice groups are shown (mean + SEM, **p < 0.01, non-
parametric Mann-Whitney t-test, aso vs wt, n = 3 per group); levels
of Ttr in each individual mouse are also shown to illustrate variation
between mice (error bars represent SEM showing technical
variations in triplicate ELISA measurements). B- The average human
SNCA mRNA levels in the striata from Thy1-aSyn mice and wt mice
groups determined by qRT-PCR, normalized to Gapdh, and relative
to the levels of endogenous Snca mRNA in the wt mice that
partially hybridize to the human SNCA primers are shown (mean +
SEM, ***p < 0.001, non-parametric Mann-Whitney t-test, aso vs wt, n
= 3 per group); levels of SNCA mRNA in each individual mouse are
also shown to illustrate variation between mice (error bars represent
SEM showing technical variation in triplicate qRT-PCR analyses.
Pearson’s test found significant correlation (r
2 = 0.6791, p < 0.043)
between the two measured expression values in A and B.
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Page 5 of 16Figure 3 Gene expression patterns changes in cellular processes affected by overexpression of SNCA. Functional categories
overrepresented in the lists of genes differentially expressed in Thy1-aSyn mice were identified using the Gene ontology (GO) database, which
implements the GO terms in three structured ontologies relating gene products on the basis of their associated biological processes, cellular
components and molecular functions; multiple overlapping GO terms (referred to as functional categories) were identified (Table 2) (p < 0.05).
Shown here are the genes expression pattern (fold changes in Thy1-aSyn mice relative to wt mice) in representative functional categories
deemed highly relevant to PD pathogenesis. A) cytoplasmic vesicle/vesicle-mediated transport (GO:0031410, GO:0016192) and synapse
(GO:0045202); B) regulation of synaptic plasticity/cell-cell signaling (GO:0048167, GO:0007267) and endocytosis (GO:0006897); C) regulation of
apoptosis (GO:0042981) plus additional apoptosis regulators identified through data-mining; the sign + after the gene symbol indicates the gene
is proapoptotic, the sign - indicates the gene antiapoptotic term and the signs +- or the term “Both” refers to ambivalent genes that can
positively and negatively regulate apoptosis; D) behavior (GO:0007610) and hormone activity (GO:0005179); E) vasculature development
(GO:0001944) and sterol metabolic process/cholesterol metabolism (GO:0016125, SP PIR_KEYWORDS: cholesterol metabolism). Most genes name
descriptions can be found in the text; otherwise in Additional file 2 Table S1.
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S1) in Thy1-aSyn mice, Pde7b and Pde10a, are predomi-
nantly expressed in the striatum and have been asso-
ciated with DArgic signaling [28,29], indicating that
SNCA may influence post-synaptic DArgic signaling in
striatal neurons through these enzymes. Interestingly,
functional alterations in post-synaptic DArgic signaling
have been detected in the striatum of these mice
[11,13]. Additionally, members of the main signal trans-
duction systems that mediate long-term potentiation
and memory were affected in Thy1-aSyn mice. Notably,
the synaptic Ca2+ signaling system seems altered, with
reduced expression of Camk2d (Ca2+/calmodulin-
dependent protein kinase II, delta) [30] (Figure 3A),
Cacnb4 (Ca2+ channel, voltage-dependent, beta 4 subu-
nit) (Figure 3B), and the (Ca2+)-activated transcription
factor Mef2c that is known to promote neuronal survival
[31] (Figure 3C), and increased expression of Camk4
(Ca2+/calmodulin-dependent protein kinase IV) (Figure
3B) [32,33]. Although inspection of the MAPK pathway
genes affected in Thy1-aSyn mice does not allow us to
surmise the status of this pathway, the decreased expres-
sion of the Fos gene (Figure 3C, D) in these mice is con-
sistent with previously reported suppression of the
MAPK pathway by elevated SNCA [34]. Thus, Ca2+
homeostasis and DArgic signaling may be affected in
the striatum of Thy1-aSyn mice.
Both behavioral and electrophysiological responses to
amphetamine, an indirect DA agonist, are profoundly
altered in Thy1-aSyn mice [11,13]. Interference with the
amphetamine response in Thy1-aSyn mice may be
mediated by the decrease of Cartpt and the increase of
Rasd2 (rasD family, member 2, a.k.a. Rhes) (Figure 3D).
Cartpt is upregulated in the striatum by amphetamine
[35], and Rasd2 has been shown to inhibit the stereo-
typy induced by co-activation of Drd1/Drd2 and by the
Drd2 receptor alone [36], reminiscent of the decreased
amphetamine-induced stereotypies observed in Thy1-
aSyn mice [13].
Alterations in the expression of synaptic vesicle cycle and
synaptic plasticity associated genes
The second group in Table 2 includes cellular mechan-
isms comprising genes encoding for components of the
synapse, cytoplasmic vesicles and cytoskeleton, which
participate in biological processes such as the synaptic
vesicle cycle, endocytosis, and synaptic plasticity, whose
deregulation is highly relevant to the pathophysiology of
neurodegenerative diseases [37,38]. At synapses, the
synaptic vesicle release cycle is a tightly regulated cas-
cade of events that involves the interplay of several pro-
teins, including cytoskeleton components, to control
synaptic vesicle mobilization between functional pools
prior to their release [38].
The results from our study suggest that SNCA may
control these processes through the transcriptional regu-
lation of genes (Figure 3A, B) whose encoded proteins
influence vesicle release and recycling such as the down-
regulation of Syn2 (Synapsin II), and Cadps2 ((Ca2
+)-dependent activator protein for secretion 2), which
positively regulate these processes [39,40]. Indeed, study
of mice lacking Snca showed that Syn2 is required to
maintain normal numbers of synaptic vesicles and to
regulate synaptic plasticity (for review see: [39]); Cadps2
has been implicated as a calcium sensor involved in
constitutive vesicle trafficking and secretion [40]. Hence,
Syn2 and Cadps2 downregulation in Thy1-aSyn mice is
consistent with recent compelling evidence showing that
modest SNCA overexpression markedly inhibits neuro-
transmitter release by a reduction in size of the synaptic
vesicle recycling pool and through a defect in the reclus-
tering of synaptic vesicles after endocytosis [41], and
suggests that this specific SNCA effect may involve tran-
scriptional repression of these genes. Support for a role
of SNCA in regulating endogenous presynaptic proteins
comes from a recent study in cultured neurons from tg
mice overexpressing modest level of SNCA [42], which
suggests that the decrease of endogenous presynaptic
proteins by excessive SNCA may lead to functional
impairments at synapses causing vesicle release inhibi-
tion [41]. Interestingly, synapsin was the most dimin-
ished of the four proteins analyzed in the study by Scott
et al. [42], which is consistent with our results (Syn2
was downregulated).
Endocytosis genes that were altered in Thy1-aSyn
mice encode for proteins involved in both the clathrin-
mediated endocytosis (CME), as well as in the activity-
dependent bulk endocytosis (ADBE), endosomal recy-
cling and early endosome. These include, Pacsin1 (Pro-
tein kinase C and casein kinase substrate in neurons 1),
and Sorl1 (Sortilin-related receptor, LDLR class A), (Fig-
ure 3B). Pacsin1 has recently been shown to be essential
for the ADBE that is triggered during increased neuro-
nal activity [43] and both ADBE and clathrin-mediated
endocytosis contribute to the replenishment of synaptic
vesicles [44]. Thus Pacsin1 upregulation in Thy1-aSyn
mice may lead to increased neurotransmitter synaptic
vesicles, which could provide a compensatory mechan-
ism for the detrimental effects of excess SNCA on
synaptic vesicles observed by Nemani et al. [41]. SORL1
has been shown to guide trafficking of amyloid precur-
sor protein (APP) into recycling (endocytic) pathways
and its decreased expression leads to the sorting of APP
into amyloid generating compartments. This suggests
that changes in SORL1 expression or function may be
mechanistically involved in Alzheimer’s disease (AD)
pathogenesis [45]. The downregulation of Sorl1 in the
Thy1-aSyn mice is of particular interest in view of
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interact in vivo and promote each other aggregation and
accumulation [46].
Genes involved in post-synaptic neurotransmitter sig-
naling in striatal neurons were also significantly affected
in Thy1-aSyn mice (Figure 3B). The expression of the
receptor genes Drd2 (DA receptor D2), Grm1 (Gluta-
mate receptor, metabotropic 1), Adora2a and Gabbr1
(g-aminobutyric acid (GABA-B) receptor, 1) was upregu-
lated in Thy1-aSyn mice. Adora2a is particularly inter-
esting because caffeine, an adenosine A2a receptor
antagonist, is protective against PD and Adora2a antago-
nists are developed for treating PD [47]. In addition,
Sh3kbp1 (SH3-domain kinase binding protein 1, a.k.a.
Cin85), also increased in Thy1-aSyn mice (Figure 3B),
has been shown to positively regulate Drd2 endocytosis
in the striatum [48]. Hence, its increased expression
may increase Drd2 endocytosis in striatal neurons in
response to DA stimulation and could explain abnormal
responses to DA receptor stimulation in striatal slices of
the Thy1-aSyn mice [11].
SNCA overexpression triggers molecular changes that
may underlie neuroprotection
The third group in Table 2 includes biological processes
involved in the regulation of fundamental cellular
mechanisms for cell transcription, cell proliferation, pro-
tein degradation and apoptosis. The expression balance
of transcription genes in the Thy1-aSyn mice is tilted
towards repression, as indicated by the repression of
more genes that positively regulate transcription, which
is consistent with the larger number of repressed genes
in these animals, as noted above. In contrast, the
changes in cell proliferation genes were evenly distribu-
ted between positive and negative regulators of this pro-
cess in Thy1-aSyn mice. In particular, alterations in the
insulin-like growth factor (IGF) system, which regulates
cell growth, proliferation, and apoptosis [49] may offer
s o m ec l u e sa st ot h ee f f e c t so fS N C Ao nt h e s ep r o -
cesses. Hence, the concerted attenuation of the expres-
sion of Igfbp6 (Igf-binding protein 6), Nov
(Nephroblastoma OVerexpressed, a.k.a. Igfbp9,o rCcn3),
and Ctgf (Connective tissue growth factor, a.k.a. Igfbp8,
or Ccn2) genes may increase the availability of Igf1 to
activate its receptor (Igf1r), which promotes motor neu-
rons survival [50] and thus could also contribute to neu-
roprotection of striatal neurons in Thy1-aSyn mice.
However, the downregulation (Table 3) of glutathione
peroxidase 3 (Gpx3), which protects cells from oxidative
damage and was found decreased in mouse striatum
after MPTP treatment [51], suggests that overexpression
of SNCA may decrease cellular defenses against oxida-
tive stress, as observed in the Thy1-aSyn mice for
nigrostriatal DArgic neurons [52].
The involvement of SNCA in the pathophysiology of
PD has been attributed in part to its oligomerization
into protofibrils that may aggregate into insoluble inclu-
sions, which then form Lewy Bodies [37]. Indeed, var-
ious size proteinase K-resistant SNCA inclusions have
been observed in the Thy1-aSyn mice used in this study
[9,10], but only small aggregates are detected in the
striatum (Zhu and Chesselet, unpublished observation).
It is interesting to consider that the repression of the
Tgm2c (Tranglutaminase 2 C polypeptide) gene (Figure
1C), which mediates protein transglutamination, may
prevent the formation of large aggregates in this brain
region [53].
The expression of apoptosis regulatory genes was con-
spicuously affected in Thy1-aSyn mice. Given that neu-
r o n a lc e l ld e a t hi sn o to b s e r v e di nt h es t r i a t u mo fP D
patients, this may provide some clues to the selective
pattern of neuronal vulnerability in the face of general
SNCA overexpression. Thus, the number of apoptosis
genes changed in Thy1-aSyn mice reached at least 25
apoptosis genes after including 8 additional genes identi-
fied through data mining searches for apoptosis regula-
tors (Table 2). In this study, the percentage of apoptosis
genes was 11% of the total affected genes. Such promi-
nent changes represent an apoptotic signature of the
response to SNCA overexpression, indicating the useful-
ness of transcriptome analysis to gain insights into
mechanisms influencing neurodegeneration. Hence, the
25 apoptotic genes were classified according to their
effect on apoptosis, as anti-apoptotic (-), pro-apoptotic
(+), and ambivalent (+ -) regulators and are shown in
Figure 3C with their expression patterns. From a func-
tional standpoint, the upregulation of anti-apoptotic
genes and the downregulationo fp r o - a p o p t o t i cg e n e s
can contribute to neuronal survival (Figure 3C), whereas
the upregulation of pro-apoptotic together with the
downregulation anti-apoptotic genes can lead to cell
death (Figure 3C). Such analysis reveals that SNCA
overexpression caused about equal number of pro-survi-
val and pro-death changes. However, the magnitude of
pro-survival changes was more pronounced. This is par-
ticularly true for two genes that were demonstrated to
have neuroprotective effects in models of AD: Ttr
(transthyretin) and Dhcr24 (24-dehydrocholesterol
reductase/seladin). Both were markedly induced in
Thy1-aSyn mice. Dhcr24 is an antiapoptotic factor that
protects neurons against oxidative stress and reduces
amyloid formation [54-56]. Ttr markedly increased
expression in Thy1-aSyn mice microarray was verified
by qRT-PCR RNA analysis (Figure 1A, B), as well as by
measuring the protein levels (Figure 2A). These verifica-
tion experiments were performed in striatal tissue that
was carefully dissected to avoid any contamination with
choroid plexuses, which contain high levels of Ttr (see
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behavioral and biochemical effects of amyloid toxicity in
murine models of AD [24], upregulation of Ttr was
found in response to nicotine, which may protect
against PD as suggested by epidemiological data [57]
and in the SNc of monkeys treated with MPTP before
the appearance of symptoms i.e. before the occurrence
of cell death [58]. Together these data and our result
suggest that Dhcr24 and Ttr may represent antiapopto-
tic pathway activated by SNCA overexpression. Interest-
ingly, 3 additional apoptosis genes altered in the
striatum of Thy1-aSyn mice, Nr4a2 (Nuclear receptor
subfamily 4, group A, member 2), Tcf7l2 (transcription
factor 7-like 2) and Slit2 (slit homolog 2) were similarly
affected in SNc of MPTP- treated monkeys in the pre-
symptomatic period [58]. Coupled to the changes in the
Igf system described above, these alterations may equip
striatal neurons with a battery of antiapoptotic options
in response to SNCA accumulation which could explain
the absence of neuronal cell death in the striatum in PD.
Affected genes in Thy1-aSyn mice may be involved in the
pathophysiology of PD
The fifth group in Table 2 encompasses biological pro-
cesses that have been associated with PD, such as lipid
metabolism, vascular development and neurogenesis.
Studies of overexpression of wt Snca in neuronal cells
suggested that Snca-polyunsaturated fatty acids (PUFA)
interactions regulate neuronal PUFA levels as well as
the oligomerization state of Snca [59]. Indeed, the con-
trol of vesicle recycling by Snca may be partly mediated
through its ability to act as a lipid chaperone to regulate
the turnover or local organization of PUFAs implicated
in clathrin-mediated endocytosis [37]. Recent studies
have suggested a role for Snca in brain lipid metabolism
through its modulation of lipid uptake and trafficking
[60]. Therefore, it is important to understand the effects
of the alterations of the expression of genes involved in
lipid metabolism in Thy1-aSyn mice (Figure 3E) such as
the upregulation of Srebf2 (sterol regulatory element-
binding factor 2) and Dhcr24; and the downregulation
Table 3 a-synuclein-regulated genes associated with neurological or vascular diseases
Hs orthologs Affymetrix (HGU-133A) Gene symbol: short description ASO mice Neurological disease
fold change p- value
200862_AT Dhcr24: 24-dehydrocholesterol reductase 6.1 2E-05 AD
206590_X_AT Drd2: dopamine receptor D2 3.3 8E-05 Al, BD, Diab.
206713_AT Ntng1: netrin G1 2.5 2E-04 Sch.
212762_S_AT Tf7l2: transcription factor 7-like 2 2.1 2E-04 Diab.
205013_S_AT Adora2a: adenosine A2a receptor 2.0 2E-05 Anx, ADHD,
201847_AT Lip1: lipase 1, cholesterol esterase 1.9 2E-03 AD
218489_S_AT Alad: aminolevulinate, δ-dehydratase 1.5 2E-04 ALS, Al, Pb Tx
203146_S_AT Gabbr1: g-aminobutyric acid receptor 1 1.5 4E-04 ADHD, Ep, Sc.
211026_S_AT Mgll: monoglyceride lipase 1.5 2E-05 Al.
209702_AT Fto: fat mass and obesity associated 1.5 1E-03 Diab.
212560_AT Sorl1: sortilin-related receptor, LDLR class A -1.5 3E-05 AD
210381_S_AT Cckbr: cholecystokinin B receptor -1.5 3E-03 PD, Sc, Diab.
205525_AT Cald1: caldesmon 1 -1.5 1E-03 Diab.
212382_AT Tcf4: transcription factor 4 -1.5 3E-03 Sc.
209189_AT Fos: FBJ osteosarcoma oncogene -1.6 6E-04 AD
203293_S_AT Lman1: lectin, mannose-binding, 1 -1.6 2E-03 At, CAD, Inf. D
209101_AT Ctgf: connective tissue growth factor -1.6 7E-05 Diab.
216248_S_AT Nr4a2: nuclear receptor subfamily. 4, group A, member 2 -1.7 5E-05 PD, ADHD, BD,
201348_AT Gpx3: glutathione peroxidase 3 (plasma) -1.9 2E-04 Diab.
204729_S_AT Stx1a: syntaxin 1A (brain) -1.9 2E-05 Diab.
202291_S_AT Mglap: matrix Gla protein -2.0 2E-05 At, Pb Tx
206577_AT Vip: vasoactive intestinal peptide -2.0 2E-05 MS
207848_AT Avp: arginine vasopressin -2.0 2E-05 Diab., Dement.
205352_AT Serpina3n/serpin p. inhibitor, cl. A member 3n -2.8 3E-05 Dement.
206622_AT Thr: thyrotropin-releasing hormone -8.0 1E-03 Hypertension
215775_AT Thbs1: thrombospondin 1 -13.0 7E-04 At, CAD
212412_AT Pdzl: PDZ and LIM domain 5 -16.0 3E-04 BD, Sc.
Abbreviations: D: Disease/Disorder; ADHD: Attention deficit hyperactivity D; AD: Alzheimer’s D; Al: Alcoholism; ALS: Amyotrophic lateral sclerosis; Anx: Anxiety D;
At: Atherosclerosis; BD: Bipolar D.; CAD: Coronary artery D; Dement: Dementia; Diab: Diabetes; Ep: Epilepsy; Hs: Homo sapiens; Inf. D: Inflammatory D; MS: Multiple
sclerosis; Pb Tx: Lead toxicity; PD: Parkinson’s D.; Sc: Schizophrenia
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Page 9 of 16of Sorl1. Srebf, a transcription factor that induces cho-
lesterol synthesis, is itself regulated by intracellular cho-
lesterol levels [61]; Dhcr24 is also involved in cholesterol
biosynthesis and as mentioned above protects neurons
against oxidative stress and neurodegeneration [54,55].
Besides being involved in the endocytosis of APP and
modulation of amyloid generation as discussed above,
Sorl1 (a.k.a. LR11) is the receptor of apolipoprotein E
(ApoE), which has been implicated in AD neurodegen-
eration [62]. Thus the expression changes in these three
genes may alter cholesterol homeostasis and suggest
that SNCA overexpression also affects lipid metabolism
in the brain at the transcriptional level.
The alteration of multiple blood vessel development
genes in the Thy1-aSyn mice could be relevant to the
pathophysiology of PD as well. Disruption of the cere-
bral microvasculature may impair cholesterol efflux
from the CNS and deficiencies in blood vessel develop-
ment could reduce cerebral blood flow with concomi-
tant depletion of nutrients, increase Ca2+, and elevated
oxidative stress [63]. The notion that excessive SNCA
interferes with vascular development is interesting, as it
has been implicated in the pathogenesis of neurodegen-
erative diseases in conjunction with cholesterol homeos-
tasis imbalances [62]. The pattern of expression of
vascular development affected genes in Thy1-aSyn mice
i ss h o w ni nF i g u r e3 Ea n dt h ef u n c t i o n so fs o m eo f
them (Ctgf, Mef2c, Tgm2) have been discussed earlier.
The expression of genes involved in neuronal differen-
tiation is markedly regulated in Thy1-aSyn mice as indi-
cated by alterations in at least 20 genes that regulate
this process (Table 2). The expression of the brain
derived growth factor (Bdnf) gene, which induces prolif-
eration and recruiting of newly born cells into the stria-
tum [64], was down-regulated in Thy1-aSyn mice
(Figure 3A). A similar decreased Bdnf expression was
reported in PD striatum [65]. BDNF mRNA is low or
absent in striatal neurons [66] but could originate in
astrocytes [67] and/or cells of the subventricular zone
that were included in the pooled tissue used for micro-
a r r a ya n a l y s i s[ 6 8 ] .T h ea l t e r a t i o n si nt h ee x p r e s s i o no f
these two genes and others neurogenesis genes raises
the possibility that SNCA overexpression may affect the
recruitment of newly born cells into the striatum and
other brain regions and could impair adult neurogenesis,
a deficit documented in similar lines of mice overex-
pressing SNCA [69].
Human diseases associated with genes affected in Thy1-
aSyn mice
The sixth and final group in Table 2 comprises genes
altered in Thy1-aSyn mice that are associated with
human diseases, namely diabetes and neurological disor-
ders. The list of genes altered in Thy1-aSyn mice was
used to find their human orthologs in the affymetrix
databases; this identified 100 (of 224) orthologs, which
were used to search the GAD of human diseases. The
identified SNCA regulated genes associated with neuro-
degenerative diseases are listed in Table 3. Having iden-
tified diabetes and neurological disorders as
predominant disease categories by this search, the
expression and functional annotations for each of these
genes was scrutinized further. A striking number of
genes altered by excessive SNCA seem to be associated
with metabolic diseases, most conspicuously with the
diabetes phenotype, which is strongly supported by
recent experimental data showing that Snca inhibited
insulin secretion in b islet cells of the pancreas [70] and
by the effect of excess SNCA on the expression of IGF
system genes in this study. In addition, most of the neu-
rological disorders in Table 3 share lipid imbalance as a
pathophysiological feature [71]. Interestingly, a diagnosis
of diabetes is more frequent in young onset PD patients
than in controls [72]. Another compelling connection is
the findings that the transcription factor Tcf7l2 was
strongly increased in Thy-aSyn mice and is heavily
deregulated in a PD paradigm using neuroepithelioma
cells chronically exposed to rotenone (manuscript in
p r e p a r a t i o n ) ,a st h i sg e n ei sp articularly linked to risk
for diabetes and appears to be essential in b-cell func-
tioning, since its loss of function in islets and variants of
TCF7L2 in humans impair glucose-stimulated insulin
secretion, which suggests that its deregulation may con-
tribute to the susceptibility for, and pathogenesis of,
type 2 diabetes [73].
Comparison to previous transcriptome analysis
Few other studies have performed comparable analysis
of gene expression in mice overexpressing SNCA.
Yacoubian et al. [18] limited their analyses to laser-cap-
t u r e dD A r g i cn e u r o n sf r o mt h eS No fm i c eo v e r e x p r e s -
sing SNCA under a different promoter, PDGFb. Another
major difference is that their study used both males and
female mice, whereas our study was limited to male
mice in view of evidence from the same group and
others indicating that gender influences gene expression
changes induced by SNCA overexpression in mouse
S N cD A r g i cn e u r o n s[ 1 8 ] ,a sw e l la st h ep a t t e r n so f
gene expression in human SNc DArgic neurons from
both normal and PD brains [74,75]. Nevertheless, a
functional categories analysis of Yacoubian et al. data
using the updated version of DAVID that we used in
this study revealed that several of the functional cate-
gories that we detected as being affected at 6 months (e.
g. phosphoproteins, synapse, synaptic function, regula-
tion of transcription, cytoskeleton, vesicles, signaling,
neurogenesis and protein oligomerization) were also
affected in the Yacoubian data set in 9 months old mice
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may affect similar functional pathways in different neu-
ronal populations, although the specific gene expression
alterations, as expected, may be cell type-specific or gen-
der-dependent. To our knowledge, changes in striatal
gene expression were only examined in one other study
[17]; however, in this case, SNCA overexpression was
driven by the tyrosine hydroxylase promoter and there-
fore, confined to DArgic neurons innervating the stria-
tum, not the striatal neurons themselves as in our study.
Therefore, the changes observed by Miller et al. (2007)
reflect changes secondary to alterations in DArgic neu-
rons, not the effects of SNCA on striatal neurons.
Nevertheless, we noticed about 20% similarity in the
genes affected in the striatum compared to the changes
we have observed. For example, 5 out of the 23 selected
genes shown in Table 2 of Miller et al. [17] were also
c h a n g e di no u rd a t as e t( T a b l eS 1 ) .T h i si sn o ts u r p r i s -
ing as the changes reported here likely reflect both a
direct effect of SNCA on striatal neurons and changes
that are secondary to SNCA induced alterations in stria-
tal input neurons, including the nigrostriatal DArgic
pathway. Previous reports of transcriptome analyses of
the SNc in male PD subjects revealed a strong enrich-
ment of pathways and cellular components relevant to
PD pathogenesis that encompassed most of the func-
tional categories associated with SNCA overexpression
in this study, including synaptic transmission, neuro-
transmitter secretion, vesicle-mediated transport, apop-
tosis, synapse, cytoskeleton, signaling, and transmission
of nerve impulse [74,75].
Conclusions
A transcriptome analysis was undertaken in striatal tis-
sue from mice overexpressing wt human SNCA under
the Thy1 promoter to elucidate biological processes
influenced by excessive SNCA levels. This promoter
confers broad transgene expression in neurons [8]. A
schematic summary of possible consequences due to
striatal gene expression changes in response to SNCA
overexpression is shown in Figure 4. The results from
this analysis suggest that the pattern of expression of
apoptotic and neuroprotective genes induced by SNCA
favors cell survival, which could explain why striatal
neurons do not degenerate in PD. Furthermore, altera-
tions in the expression pattern of genes associated with
synaptic function in the Thy1-aSyn mice are consistent
with recent evidence indicating that excessive SNCA
causes deficits in neurotransmitter release by inhibiting
synaptic vesicle reclustering after endocytosis [41]; such
alterations may lead to derangements at the synapses
evident by the inhibition of neurotransmitter release
which may impair synaptic plasticity, cause behavioral
changes and contribute to neurodegeneration and even-
tually clinical PD.
Methods
Transgenic mice overexpressing human wt SNCA, and
striatal tissue preparation
Animal care was conducted in accordance with the U. S.
Public Health Service G u i d ef o rt h eC a r ea n dU s eo f
Laboratory Animals and procedures were approved by
the University of California, Los Angeles (UCLA), I.A.C.
U. Committee. Transgenic (tg) mice overexpressing
human wt SNCA under the Thy-1 promoter (Thy1-
aSyn) created previously [8] in a mixed C57BL/6-DBA
background were kept in this background by breeding
mutant females with wt males. Only male mice were
used in the study. The genotype of all tg and wt mice
was verified by PCR analysis of tail DNA. Animals were
maintained on a 12 hr light/dark cycle with free access
to water and food. Six-month old male Thy1-aSyn and
wt littermates were sacrificed by decapitation. For
microarray analysis, whole striata from each hemisphere
were immediately dissected and pooled for each brain.
Tissue was permeated in RNAlater (Qiagen, Valencia,
CA), frozen in liquid nitrogen, and stored at - 80°C
until used for RNA preparation. For PCR verification of
transcriptional changes and for protein extracts prepara-
tion, brains from 5 male Thy1-aSyn and 5 wt littermates
were obtained as above but then the brains were placed
in a metal brain mold with grooves to ensure reproduci-
ble cutting of thick brain slices. A first coronal cut was
made with a razor blade to remove the frontal part of
the brain (at bregma + 1 mm, at the anterior level of
striatum). The following 1 mm coronal slice (including
the striatum but no globus pallidus) was used to dissect
out striatal tissue. A horizontal cut was made through
the anterior commissures to exclude the nucleus accum-
bens. One cube of striatum was dissected out from each
hemisphere, taking care not to include any corpus callo-
sum, choroid plexus, or subventricular zone. Samples
were stored at -80° until further processing.
RNA preparation and microarray processing and data
analysis
Total RNA was extracted from striata of Thy1-aSyn and
wt littermates (all males) with Trizol™ (Invitrogen,
Carlsbad, CA), followed by a clean-up step with
RNeasy™ columns (Qiagen) and RNA integrity check
using a Bioanalyzer (Agilent Tech., Foster city, CA).
RNA samples were pooled, one pool representing the
six control wt mice and the other representing the six
SNCA overexpressing animals. After synthesis, using
Superscript™ (Invitrogen) and labeling using the ENZO
labeling kit (Affymetrix Inc. ,S a n t aC l a r a ,C A ) ,c R N A
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Chip
® arrays (Affymetrix) following the manufacturer’s
protocol at the UCLA microarray core facility. Signifi-
cant differential gene expression between pooled tg and
wt samples was ascertained by estimation of signal log2
ratios (or fold changes in expression values), after qual-
ity control checks, data normalization and estimating
expression values using the Affymetrix MAS 5.0
Software. After pairwise comparisons and filtering of
this gene list using the following criteria: change p-value
< 0.005 for induce genes, change p-value > 0.995 for
decreased genes, signal log2 ratio > 0.6 (> 1.52 fold
change), excluding probes called absent in both groups,
a list of 233 differentially expressed genes was generated.
We used various statistical softwares and databases to
ascertain pathways affected by overexpression of SNCA
Figure 4 Schematic summary of striatal gene expression changes in response to SNCA overexpression. Green color is used to represent
down-regulated and red color to represent up-regulated genes or pathways. Detailed descriptions and interpretations on gene and pathway
changes can be found in the results and discussion.
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gene list, including, the functional annotation tools
accessible through DAVID (Database for Annotation,
Visualization and Integrated Discovery, http://david.
abcc.ncifcrf.gov) [21]. Additional apoptosis-related genes
in the list of regulated genes were identified through
data-mining searches conducted on various databases,
including the University of Michigan list of apoptosis
regulators (http://www-personal.umich.edu/~ino/List/
AList.html). In addition, we performed literature
searches on genes associated with the detected path-
ways, to ascertain their functions.
Quantitative Real-Time PCR validation of results
Quantitative real-time PCR (qRT-PCR) analysis was per-
formed with both pooled striatal RNA samples used in
the microarray analysis and individual striatal RNA sam-
ples from 3 male Thy1-aSyn and 3 male control wt lit-
termates from which cubes of striatal tissue were
dissected out as described. Total RNA (500 ng) from
each sample was reverse transcribed using Superscript
III cDNA Synthesis Kit (Invitrogen). Primer sets for
each gene (see Additional file 3, Table S2) were
designed using the primer design program implemented
in the Vector NTI Software (Invitrogen), and custom
made by Life Technology (Invitrogen). All PCR reactions
were performed using the QuantiTect SYBR GreenTM
qRT-PCR kit (Qiagen), and run in triplicate in the ABI
PRISM 7700 System (Applied Biosystems Inc, Fullerton,
CA). All primer sets had PCR efficiencies comparable to
the internal control used, Gapdh (glyceraldehyde-3-
phosphate dehydrogenase), as determined by analysis of
serial dilutions of template (10-fold); thus allowing the
comparative threshold cycle Ct method to be used for
relative quantification of the transcripts [76] by compar-
ing the determined target Ct values to the Ct for
Gapdh, thereby normalizing for small differences in
starting template amounts. Data (see Additional file 4,
Tables S3-ABCD) was analyzed using Prism 5.0 (Graph-
pad Software Inc., San Diego, CA), mean and standard
errors were determined for each analyzed gene in each
mice group and the one-way Mann-Whitney t-test
(non-parametric) was used to estimate significance of
deviations (p < 0.05) from the control samples. Pearson’s
test was used to quantify the magnitude and direction of
the correlation between microarray and qRT-PCR
assessed expression values.
Protein extracts preparation and transthyretin
measurement by ELISA
Striatal tissue samples from 6 months old Thy1-aSyn
mice and wt littermates were homogenized and soni-
cated in a mild lysis buffer (10 mM CHAPS, 0.15 M
NaCl, 0.01 M NaH2PO4, 2 mM EDTA, 50 mM NaF,
0.2 mM NaVa, 10 U/ml aprotinine, 20 U/ml DNAse I, 2
ug/ml RNAse, 1% mercaptoethanol) and centrifuged for
2 min, at 12,000 × g, at 4°C; and the soluble fraction
was collected and frozen until used. The insoluble pellet
was further sonicated in a stronger lysis buffer (150 mM
N a C l ,1 0m MN a H 2 P O 4 ,1m ME D T A ,2 %S D S ,a n d
0.5% deoxycholate) containing the same protease inhibi-
tor mixture. The resulting homogenate was centrifuged
and the detergent-soluble fraction was collected, and
frozen until used. To measure detergent-soluble frac-
tion, a 1:100 dilution was made with PBS. To determine
total amount of mouse transthyretin (Ttr), measurement
of both fractions was done by ELISA as described by
Purkey et al. [23]. Briefly, appropriate dilutions of anti-
gen, pure Ttr (Sigma Co. St. Louis, MO), and striatal tis-
sue samples (three 5-10 fold dilutions), were coated in
duplicates onto 96-well Immobilon plates overnight at
4°C in PBS buffer. After washing and blocking with
0.05% Tween 20/5% non-fat powdered milk/1xPBS at
37°C for 1 h; primary goat anti-human TTR antibody
(C-20: sc-8104, Santa Cruz Biotech. Inc. CA), was used
at a 1:500 dilution and secondary antibody (donkey anti-
goat-HRP, sc:2020, Santa Cruz) was used at a 1:1000
dilution. Detection was performed with tetramethylben-
zidine (TMB) (Sigma) and stopped with sulfuric acid.
Plates were read in a Kinetic microplate reader (Molecu-
lar Devices, Sunnyvale, CA) at 450 nm and analysis was
performed using the SoftMax Pro LS software (Molecu-
lar Devices). Ttr concentrations were normalized to
total striatal protein, as determined by Bradford assay
(BioRad Labs, Hercules, CA). Data was analyzed using
Prism 5.0 (Graphpad Software Inc.) mean and standard
errors were determined for each group and one-way
Mann-Whitney test (t test non-parametric) was used
with p < 0.05 considered significant. Pearson’sc o r r e l a -
tion test was used to quantify the magnitude and direc-
tion of the correlation between Ttr protein levels and
SNCA mRNA (assessed by qRT-PCR) expression values.
Additional material
Additional file 1: Figure S1. Normalization scatter plot between the
a-synuclein overexpressing (ASO) transgenic (tg) mice and the
baseline control wild type (wt) mice illustrating the quality of the
data.
Additional file 2: Table S1. List of genes differentially expressed
genes between a-Synuclein overexpressing (ASO) mice and wild
type (wt) mice in striatal tissue at 6 months. A gene probe was
considered differentially expressed if it reported signal log2 ratio > 0.6 (>
1.52 fold change), after pairwise comparison using the Affymetrix MAS
5.0 software with change p-value < 0.005 for induce genes, and change
p-value > 0.995 for decreased genes. 96 genes were upregulated
(shaded in pink), whereas 137 genes showed decreased (shaded in
green) expression in the ASO samples. The probes from this list were
used to identify overrepresented functional categories using DAVID listed
in Table 2 and illustrated in Figure 3.
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Page 13 of 16Additional file 3: Table S2. Supplementary table listing the primer
sets used for qRT-PCR analysis to corroborate microarray analysis
results.
Additional file 4: Table S3-ABCDE. Supplementary tables listing
data used for qRT-PCR results comparisons. (A) the qRT-PCR data
used for the statistical analyses for pooled samples in Figure 1A and the
microarray fold change value for each of the compared transcript (B) the
t-test result for each individual transcript in Figure 1A, (C) the qRT-PCR
data used for the statistical analyses for non-pooled samples in Figure 1B
and the microarray fold change value for each of the compared
transcript (D) the t-test result for each individual transcript in Figure 1B,
and(E) The correlation analysis results between the microarray data and
qRT-PCR data in Figures 1A and 1B. Additional detection statistics and
fold change values for each of these probe sets and other probe sets for
differentially expressed transcripts is shown in Table S1.
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